NCT01772147 - Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks. | Biotech Hunter

Enrollment

608

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

Umeclidinium bromide 62.5mcg

Inhalation powder

DRUG

Umeclidinium bromide 125mcg

Inhalation powder

DRUG

Fluticasone propionate 250mcg/Salmeterol 50mcg

Inhalation powder

Trial Locations (55)

23229

GSK Investigational Site, Richmond

23249

GSK Investigational Site, Richmond

23606

GSK Investigational Site, Newport News

28207

GSK Investigational Site, Charlotte

29303

GSK Investigational Site, Spartanburg

29678

GSK Investigational Site, Seneca

29732

GSK Investigational Site, Rock Hill

32720

GSK Investigational Site, DeLand

32822

GSK Investigational Site, Orlando

33603

GSK Investigational Site, Tampa

36608

GSK Investigational Site, Mobile

45245

GSK Investigational Site, Cincinnati

63301

GSK Investigational Site, Saint Charles

70584

GSK Investigational Site, Sunset

70868

GSK Investigational Site, Ostrava - Poruba

83814

GSK Investigational Site, Coeur d'Alene

85006

GSK Investigational Site, Phoenix

92647

GSK Investigational Site, Huntington Beach

2520024

GSK Investigational Site, Viña del Mar

3460001

GSK Investigational Site, Talca

4070038

GSK Investigational Site, Concepción

7500710

GSK Investigational Site, Santiago

7500800

GSK Investigational Site, Santiago

8207257

GSK Investigational Site, Puente Alto - Santiago

8880465

GSK Investigational Site, Santiago

Unknown

GSK Investigational Site, Viña del Mar

GSK Investigational Site, Santiago

360 09

GSK Investigational Site, Karlovy Vary

278 01

GSK Investigational Site, Kralupy nad Vltavou

410 02

GSK Investigational Site, Lovosice

772 00

GSK Investigational Site, Olomouc

301 00

GSK Investigational Site, Pilsen

323 00

GSK Investigational Site, Pilsen

140 46

GSK Investigational Site, Prague

150 00

GSK Investigational Site, Prague

170 00

GSK Investigational Site, Prague

390 19

GSK Investigational Site, Tábor

415 10

GSK Investigational Site, Teplice

82-300

GSK Investigational Site, Elblag

81-384

GSK Investigational Site, Gdynia

86-300

GSK Investigational Site, Grudziądz

88-100

GSK Investigational Site, Inowrocław

31-024

GSK Investigational Site, Krakow

63-400

GSK Investigational Site, Ostrów Wielkopolski

64-920

GSK Investigational Site, Piła

01-192

GSK Investigational Site, Warsaw

50-088

GSK Investigational Site, Wroclaw

705-717

GSK Investigational Site, Daegu